RS2120 - Upadacitinib

Atopic dermatitis - INITIATION	2
Atopic dermatitis - CONTINUATION	
Crohn's disease – adult - INITIATION	3
Crohn's disease – adult - CONTINUATION	3
Crohn's disease – children - INITIATION	4
Crohn's disease – children - CONTINUATION	4
Rheumatoid Arthritis - CONTINUATION	2
Rheumatoid Arthritis (patients previously treated with adalimumab or etanercept) - INITIATION	2
Ulcerative colitis - INITIATION	4
Ulcerative colitis - CONTINUATION	4

I confirm that the above details are correct:

Signed: Date:

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

RESCRIBER			PATIENT:
ame:			Name:
'ard:			NHI:
padacit	tinik)	
NITIATIO Re-assess	N – I	Rheur It requ	natoid Arthritis (patients previously treated with adalimumab or etanercept) ired after 6 months
Prerequis	sites	(tick b	oxes where appropriate)
and	0	The i	ndividual has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis
	or	0	The individual has experienced intolerable side effects with adalimumab and/or etanercept
		\bigcirc	The individual has received insufficient benefit from at least a three-month trial of adalimumab and/or etanercept such that they do not meet the renewal criteria for rheumatoid arthritis
and		0	Rituximab is not clinically appropriate
	or	0	The individual is seronegative for both anti-cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor
		an	O The individual has been started on rituximab for rheumatoid arthritis in a Health NZ Hospital
			O The individual has experienced intolerable side effects with rituximab or
			At four months following the initial course of rituximab the individual has received insufficient benefit such that
			they do not meet the renewal criteria for rheumatoid arthritis
CONTINU	JATIC)N – F	
Re-assess	smen	t requ (tick b	theumatoid Arthritis ired after 6 months inoxes where appropriate) wing 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline
Re-assess Prerequis	smen	t requ (tick b	theumatoid Arthritis ired after 6 months inoxes where appropriate) wing 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from
Prerequis Or NITIATIO Re-assess	Sites O O O O Simen	Follo On s base Atopic	theumatoid Arthritis ired after 6 months inoxes where appropriate) wing 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from
Prerequis Or NITIATIO Re-assess	Sites O O O O Simen	Follo On s base Atopic (tick b	theumatoid Arthritis ired after 6 months oxes where appropriate) wing 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline ubsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from line c dermatitis ired after 6 months
or NITIATIO Re-assess Prerequis	ON - Assmen	Follo On s base Atopic t required (tick b	theumatoid Arthritis ired after 6 months invited after 6 months initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from line c dermatitis ired after 6 months invited after 6 months
or NITIATIO Re-assess Prerequis	ON - Anna Sites	Follo On s base Atopic Indiv	theumatoid Arthritis ired after 6 months invited after 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from line c dermatitis ired after 6 months invited
or NITIATIO Re-assess Prerequis	ON - Andrews and and and and	Follo On s base Atopic (tick b	theumatoid Arthritis ired after 6 months invited interest appropriate) wing 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline subsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from line c dermatitis ired after 6 months invited
or NITIATIO Re-assess Prerequis	on and and	Follo On s base Atopic (tick b Indiv	theumatoid Arthritis ired after 6 months oxes where appropriate) wing 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline ubsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from line c dermatitis ired after 6 months oxes where appropriate) dual is currently on treatment with upadacitinib for atopic dermatitis and met all remaining criteria prior to commencing treatment Individual has moderate to severe atopic dermatitis, severity as defined by an Eczema Area and Severity Index (EASI) score of greater than or equal to 16 or a Dermatology Life Quality Index (DLQI) score of greater than or equal to 10 Individual has received insufficient benefit from topical therapy (including topical corticosteroids or topical calcineurin inhibitors) for a 28-day trial within the last 6 months, unless contraindicated to all Individual has trialled and received insufficient benefit from at least one systemic therapy for a minimum of three months (eg
or NITIATIO Re-assess Prerequis	ON - Andrews and and and and	Follo On s base Atopic (tick b Indiv	Itheumatoid Arthritis ired after 6 months oxes where appropriate) wing 6 months' initial treatment, the individual has experienced at least a 50% decrease in active joint count from baseline ubsequent reapplications, the individual has experienced at least a continuing 30% improvement in active joint count from line c dermatitis ired after 6 months oxes where appropriate) dual is currently on treatment with upadacitinib for atopic dermatitis and met all remaining criteria prior to commencing treatment Individual has moderate to severe atopic dermatitis, severity as defined by an Eczema Area and Severity Index (EASI) score of greater than or equal to 16 or a Dermatology Life Quality Index (DLQI) score of greater than or equal to 10 Individual has received insufficient benefit from topical therapy (including topical corticosteroids or topical calcineurin inhibitors) for a 28-day trial within the last 6 months, unless contraindicated to all Individual has trialled and received insufficient benefit from at least one systemic therapy for a minimum of three months (eg ciclosporin, azathioprine, methotrexate or mycophenolate mofetil), unless contraindicated to all An EASI assessment or DLQI assessment has been completed for at least the most recent prior treatment course, preferably

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

July 2025

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:			
Name:	Name:			
Ward:	NHI:			
Upadacitinib - continued				
CONTINUATION – Atopic dermatitis Re-assessment required after 12 months Prerequisites (tick boxes where appropriate) Individual has received a 75% or greater reduction in EASI score upadacitinib	e (EASI 75) as compared to baseline EASI prior to commencing			
or O Individual has received a DLQI improvement of 4 or more as compared to baseline DLQI prior to commencing upadacitinib				
INITIATION – Crohn's disease – adult Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)				
Individual has active Crohn's disease				
CONTINUATION – Crohn's disease – adult Re-assessment required after 2 years Prerequisites (tick boxes where appropriate)				
O CDAI score has reduced by 100 points from the CDAI score when or O HBI score has reduced by 3 points from when individual was init or O CDAI score is 150 or less or O HBI score is 4 or less Or O The individual has experienced an adequate response to treatment.	iated on biologic therapy			

I confirm that the above details are correct:	
Signed:	Date:

I confirm that the above details are correct:

Signed: Date:

HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

July 2025

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:				
Name:	Name:				
Ward:	NHI:				
Upadacitinib - continued					
ITIATION – Crohn's disease – children e-assessment required after 6 months ererequisites (tick boxes where appropriate)					
or Individual is currently on treatment with upadacitinib for Crohr O Child has active Crohn's disease	n's disease and met all remaining criteria prior to commencing treatment				
and	therapy for Crohn's disease and has experienced intolerable side ria				
Child meets the initiation criteria for prior bid and Other biologic therapies for Crohn's disease					
	, v				
CONTINUATION – Crohn's disease – children Re-assessment required after 2 years Prerequisites (tick boxes where appropriate)					
O PCDAI score has reduced by 10 points from when the child was initiated on treatment O PCDAI score is 15 or less Or O The child has experienced an adequate response to treatment, but PCDAI score cannot be assessed Note: Indications marked with * are unapproved indications.					
INITIATION – Ulcerative colitis Re-assessment required after 6 months Prerequisites (tick boxes where appropriate)					
O Individual is currently on treatment with upadacitinib for ulcera	ative colitis and met all remaining criteria prior to commencing treatment				
Individual has active ulcerative colitis	ogic therapy for ulcerative colitis and has experienced intolerable side				
O Individual meets the initiation criteria for pridand O Other biologic therapies for ulcerative colitis					
CONTINUATION – Ulcerative colitis Re-assessment required after 2 years Prerequisites (tick boxes where appropriate)					
The SCCAI score has reduced by 2 points or more from the S					
On score has reduced by 10 points of more from the POC	7.1 300/6 WHOTH the individual was initiated on treatment				
Re-assessment required after 2 years Prerequisites (tick boxes where appropriate) O The SCCAI score has reduced by 2 points or more from the S					